Improved survival for patients with brain metastases who are ≤50 years old and receive SRS alone, without whole brain RT
Affirms ASTRO’s 2014 Choosing Wisely® recommendation for SRSCancer patients with limited brain metastases (one to four tumors) who are ≤50 years old should receive stereotactic radiosurgery (SRS) without whole brain radiation therapy (WBRT), according to a study available online, open-access, and published in the March 15, 2015 issue of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO). For patients ≤50 years old who received SRS alone, survival was improved by 13